Bank of New York Mellon Corp Decreases Stake in Bristol Myers Squibb Company $BMY

Key Points

• Bank of New York Mellon reduced its Bristol Myers Squibb stake by 6.4% in the second quarter, selling 1.48 million shares but retaining 21.82 million shares valued at approximately $1.26 billion.
• Bristol Myers Squibb reported strong quarterly results, with EPS of $2.04 versus the $1.60 consensus and revenue of $12.97 billion, up 5.7% year over year. The company also pays a $0.63 quarterly dividend, representing a 3.8% yield.
• Investor sentiment remains broadly positive: institutional investors own 76.41% of the stock, while analysts assign BMY a consensus “Moderate Buy” rating with an average price target of $66.06.

Bank of New York Mellon Corp lessened its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 6.4% in the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 21,821,384 shares of the biopharmaceutical company's stock after selling 1,479,953 shares during the quarter. Bank of New York Mellon Corp owned 1.07% of Bristol Myers Squibb worth $1,257,348,000 as of its most recent filing with the SEC.

Other hedge funds have also modified their holdings of the company. Norges Bank acquired a new position in shares of Bristol Myers Squibb in the fourth quarter worth about $1,947,272,000. AQR Capital Management LLC increased its holdings in Bristol Myers Squibb by 172.6% during the 4th quarter. AQR Capital Management LLC now owns 25,796,905 shares of the biopharmaceutical company's stock worth $1,391,485,000 after purchasing an additional 16,332,924 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Bristol Myers Squibb by 13.1% in the 4th quarter. Geode Capital Management LLC now owns 52,638,346 shares of the biopharmaceutical company's stock valued at $2,837,026,000 after purchasing an additional 6,084,046 shares in the last quarter. Man Group plc grew its position in shares of Bristol Myers Squibb by 280.4% during the second quarter. Man Group plc now owns 7,465,845 shares of the biopharmaceutical company's stock worth $345,594,000 after buying an additional 5,503,391 shares in the last quarter. Finally, SG Americas Securities LLC grew its position in shares of Bristol Myers Squibb by 153.8% during the first quarter. SG Americas Securities LLC now owns 8,910,032 shares of the biopharmaceutical company's stock worth $540,393,000 after buying an additional 5,399,407 shares in the last quarter. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

Bristol Myers Squibb Price Performance

Shares of NYSE:BMY opened at $65.54 on Friday. The company has a quick ratio of 1.38, a current ratio of 1.53 and a debt-to-equity ratio of 1.89. Bristol Myers Squibb Company has a fifty-two week low of $42.52 and a fifty-two week high of $68.64. The firm has a 50-day simple moving average of $60.35 and a 200 day simple moving average of $59.31. The company has a market cap of $133.88 billion, a PE ratio of 14.44, a P/E/G ratio of 0.18 and a beta of 0.22.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last issued its earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 EPS for the quarter, beating analysts' consensus estimates of $1.60 by $0.44. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.The company had revenue of $12.97 billion during the quarter, compared to the consensus estimate of $11.74 billion. During the same period in the previous year, the firm posted $1.46 earnings per share. Bristol Myers Squibb's quarterly revenue was up 5.7% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. On average, sell-side analysts anticipate that Bristol Myers Squibb Company will post 6.95 EPS for the current year.

Bristol Myers Squibb Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, August 3rd. Stockholders of record on Thursday, July 2nd were given a dividend of $0.63 per share. The ex-dividend date was Thursday, July 2nd. This represents a $2.52 annualized dividend and a dividend yield of 3.8%. Bristol Myers Squibb's dividend payout ratio is currently 55.51%.

Key Stories Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers Squibb announced a collaboration with Chai Discovery to use artificial intelligence for antibody discovery. The partnership could improve the speed and efficiency of developing new therapies, although financial terms and the near-term earnings impact were not disclosed. Chai Discovery collaboration with Bristol Myers Squibb
• Positive Sentiment: An update on the Phase 1 study of navlimetostat indicates continued progress in Bristol Myers Squibb’s early-stage pipeline. The program remains experimental, so any commercial benefit is still distant and uncertain. Bristol Myers Squibb navlimetostat study update
• Positive Sentiment: Hematogenix said its minimal residual disease assay supported the FDA’s accelerated approval of Bristol Myers Squibb’s ZENBEXUS™, described as the first approved CELMoD therapy for multiple myeloma. The approval could expand the company’s oncology opportunity, though accelerated approvals typically require confirmatory evidence. Hematogenix assay and ZENBEXUS approval
• Positive Sentiment: Unusually heavy call-option activity, with 55,757 calls purchased—more than double the average volume—signals increased speculative interest in BMY. Options activity is not confirmation of a sustained rally and can increase volatility.
• Positive Sentiment: Analyst coverage continues to characterize BMY as an attractive value stock, supported by its relatively low valuation and income potential. A separate comparison also frames Bristol Myers Squibb as a potential bargain versus AstraZeneca, though these are opinion-based assessments. Zacks BMY value-stock analysis
• Neutral Sentiment: Articles discussing a covered-call strategy emphasize income generation rather than a bullish outlook for capital appreciation. The strategy may appeal to yield-focused investors but can limit upside if the shares rise sharply. Bristol Myers Squibb options income strategy
• Neutral Sentiment: A report on Aktis Oncology, which has attracted interest from Bristol Myers Squibb and other large pharmaceutical companies, highlights potential future deal activity but does not announce a transaction or create an immediate financial impact for BMY. Pharmaceutical interest in Aktis Oncology

Analyst Ratings Changes

A number of research analysts have commented on BMY shares. Wells Fargo & Company set a $65.00 price objective on shares of Bristol Myers Squibb and gave the company an "equal weight" rating in a research note on Friday, July 31st. Bank of America cut their target price on shares of Bristol Myers Squibb from $67.00 to $66.00 and set a "buy" rating on the stock in a research note on Friday, July 10th. Weiss Ratings raised shares of Bristol Myers Squibb from a "hold (c+)" rating to a "buy (b-)" rating in a research report on Tuesday. Argus upgraded Bristol Myers Squibb from a "hold" rating to a "buy" rating and set a $75.00 price target for the company in a research note on Wednesday, August 5th. Finally, Raymond James Financial assumed coverage on Bristol Myers Squibb in a report on Wednesday, August 5th. They issued a "strong-buy" rating for the company. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $66.06.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source